Clinton Evbota Trial, Should I Bag My Grass Clippings After Overseeding, Wild Kratts Games On Youtube, Bad Night Quotes, Square Black Plastic Buckets With Lids, Wren And Martin Book Pdf, Red Rock Grill Brunch Menu, Marianna Hill Net Worth, What Does The Ghost Emoji Mean On Tinder, Delhi To Mathura Distance Via Yamuna Expressway, " /> Clinton Evbota Trial, Should I Bag My Grass Clippings After Overseeding, Wild Kratts Games On Youtube, Bad Night Quotes, Square Black Plastic Buckets With Lids, Wren And Martin Book Pdf, Red Rock Grill Brunch Menu, Marianna Hill Net Worth, What Does The Ghost Emoji Mean On Tinder, Delhi To Mathura Distance Via Yamuna Expressway, " />

guardant health investment thesis

 In Uncategorized

Thrive Earlier Detection Corp., Cambridge, Mass. After back-to-back declines sequentially, the total test volumes in Q3 2020 have jumped ~21.3% from the previous quarter. Backed by better payer coverage for its late-stage cancer detection test, Guardant Health, Inc. has seen its top-line rising more than a two-fold from the previous year. The regulatory signoff should raise hopes for Guardant’s broad portfolio of cancer tests, which aim to detect all stages of the disease through liquid biopsy. By comparison, the company's … A subsequent respite in the virus spread will likely accelerate the recovery in test volumes as patients eventually return to doctors’ offices to seek cancer care, something they cannot postpone indefinitely. When they arrive on the scene, investors flock to them. Meanwhile, thanks to advances in genomics, precision-driven cancer treatments are gaining momentum. Anna has 6 jobs listed on their profile. The initial investment has delivered a return of over 360% in less than 20 months. At that point, an initial investment of $10,000 in Guardant Health's IPO would have been worth $46,714. The burst in test volume growth seen in 2019 has come to a grinding halt. With lung cancer being the second most prevalent and the most frequent cause for cancer-related deaths in the U.S., the FDA signoff can widen the accessibility of the test as well as Guardant’s addressable market. So how much would that $10,000 investment in the company's IPO be worth now? Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. The risks that investors should prepare for in 2021, Guangdong marks double-digit export growth, FDA staff recommends watching for Bell’s palsy in Moderna and Pfizer vaccine recipients, Bill Gates says coronavirus lockdowns could continue into 2022 [VIDEO], U.S. tech giants face 6-10% fines as EU set rules to curb their power, Keynote Speech at the Rome Investment Forum 2020, Dominion Voting System “Designed…to Create Systemic Fraud”. Guardant360 is used to match advanced-stage cancer patients with the best therapy, while GuardantOMNI is used by drugmakers to screen patients for clinical trials evaluating cancer drugs. Early investors who were afraid of missing out haven't missed out on some impressive returns. An even greater opportunity for Guardant Health, though, lies with its LUNAR liquid biopsies, which are currently available for research use only. Via SeekingAlpha.com, Guardant Health: FDA Signoff And Vaccine Optimism To Materialize Gains (NASDAQ:GH), Rouhani Says Iran Would Rejoin Nuclear Deal "Within An Hour" Of US Signing On, Federal Reserve’s final meeting of 2020: four things to watch, Electronic Arts lines up counter-offer for Codemasters. Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. Guardant Health delivered these tremendous gains the old-fashioned way. The institutional investor bought 8.7 million shares of the stock in a transaction took place on 6/30/2020. LUNAR-2 could enable the detection of cancer at early stages. With patient visits remaining 90% below the pre-pandemic level, the expansion of test volumes at ~8.0% YoY in Q3 2020 stands far below the ~76.6% YoY growth in 2019. Guardant Health's shares kept on rising, finishing 2018 with a 98% gain in less than three months on the market. Yet, the vaccine hopes could reverse the pandemic-related slowdown. As the company’s long-term prospects in early cancer detection and the precision-oncology outweigh the near-term risks from COVID-19, Guardant is a compelling ‘Buy’ for us. The consensus estimate for 2020 reflects the gloomy outlook. I don't think so. Cumulative Growth of a $10,000 Investment in Stock Advisor, If You Invested $10,000 in Guardant Health's IPO, This Is How Much Money You'd Have Now @themotleyfool #stocks $GH, reported impressive results in February 2019, Why Guardant Health Tumbled by Over 10% on Monday. Investment Thesis. Sources: The Author; Data from Seeking Alpha and the Author Estimates. With EV at 28.5x of 12-month forward sales, the company trades at a ~24.8% discount to its 2019 average of ~37.9x. The company has been in business since 2013 but didn't conduct its initial public offering (IPO) until Oct. 4, 2018. One of the most important of these was the decision by Palmetto GBA to make Guardant360 the first (and, so far, only) liquid biopsy to receive broad coverage for use in most types of advanced solid tumors. Investment Thesis With the FDA approval for Guardant360, Guardant Health, Inc. (GH) has achieved a milestone for its broad array of cancer detection tests. I am not receiving compensation for it (other than from Seeking Alpha). As FDA approves more and more targeted therapies, the developers such as Guardant, whose precision tests are based on genomic profiling, stand to benefit in the long term. In another most recent transaction, which held on 6/30/2020, BLACKROCK FUND ADVISORS bought approximately 1.4 million shares of Guardant Health Inc. Google+. I’m convinced that Guardant Health can deliver mind-blowing returns over the next 10 years as well. Stocks. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article. window.SA = {"App":{"name":"SA","fullName":"Seeking Alpha","type":"regular","host":"https://seekingalpha.com","financeApiHost":"https://finance.api.seekingalpha.com","emailHost":"https://email.seekingalpha.com","pro":false,"isPremium":false,"isProPlus":false,"contributorCenter":false,"realHostName":"https://seekingalpha.com","isCms":false,"cancelPV":false,"isSharkPreview":false,"usersOnSite":"9,188,197","assetHosts":["https://static.seekingalpha.com","https://static1.seekingalpha.com","https://static2.seekingalpha.com","https://static3.seekingalpha.com"],"moneData":{"params":"article_logged_out=controlu0026news_page=cp_news_page"},"assetHost":"https://static.seekingalpha.com","userEchoHost":"https://feedback.seekingalpha.com","unbounceHost":"https://subscriptions.seekingalpha.com","env":{"dev":false,"staging":false,"production":true,"test":false},"gaAccountId":"UA-142576245-1","pianoAccountId":"CWJjPp7cpu","comscoreAccountId":8500672,"fbAppId":"2459764930747368","googleClientId":"853676697728-j4qpq4pfialt14ibl9ppa3tk37m6kc9e.apps.googleusercontent.com","twitterAccountName":"SeekingAlpha","rollbarToken":"5edf110be2fc4cecb32637fc421111e2","perimeterXAppId":"PXxgCxM9By","embedlyKey":"a6da93fdfc49472099ce63260954716b","mp":false,"chat":{"host":"https://rc.seekingalpha.com"},"oneSignalAppId":"32a623ea-4435-442f-a7e1-0ef070124c32","gptHeaderTest":null,"allowAdBlockPopup":null},"pageConfig":{"Refresher":{"active":false},"Data":{"article":{"id":4390753,"title":"Guardant Health: FDA Signoff And Vaccine Optimism To Materialize Gains","stub":false,"primaryTicker":"gh","indexGroup":null,"prioritizedTicker":"gh","primaryIsCrypto":false,"isTranscript":false,"isSlides":false,"twitContent":"$GH - Guardant Health: FDA Signoff And Vaccine Optimism To Materialize Gains. With the FDA approval for Guardant360, Guardant Health, Inc. (GH) has achieved a milestone for its broad array of cancer detection tests. Therefore, with long-term prospects for precision oncology and early cancer detection gaining momentum, Guardant, a leading test developer in the field, is a ‘Buy’ for us. Assuming the historical average of trading multiple, our more sanguine revenue forecast for the next 12-months indicates an attractive premium offsetting the near-term concerns over growth. Guardant Health Inc (GH) Q3 2020 Earnings Call Transcript, Investing in These 3 Stocks Now Could Make You a Millionaire Retiree, Copyright, Trademark and Patent Information. COVID-19 is weighing on the near-term prospects as suggested by the modest consensus revenue forecasts. However, it doesn’t have repeat customers like Guardant Health where patients need to get retested every so often. I am not receiving compensation for it (other than from Seeking Alpha). Assuming a faster pickup in test volumes than suggested by the consensus, we project ~42.1 – 47.2% YoY growth in LTM revenue for the company, leading to ~$385.5 – ~$399.3 million in revenue. The stock closed at an all-time high on Feb. 21, 2020. Since its IPO in 2018, the company scored its most significant clinical milestone. The lukewarm growth forecasts seen in consensus revenue and the … Guardant Health (NASDAQ:GH) definitely has such an X factor. Guardant Health: FDA Signoff And Vaccine Optimism To Materialize Gains. Yet, amid pandemic-related concerns over its revenue growth, the first-ever regulatory win hasn’t sparked the share price rally that usually follows such announcements. A look at the technology behind Guardant's diagnostics system, and some speculation as to which companies might be a potential suitor in a buyout Guardant Health's shares sank as much as 34% off the highs from earlier in the year before rebounding. With the FDA approval for Guardant360, Guardant Health, Inc. (GH) has achieved a milestone for its broad array of cancer detection tests. The key to this success was the skyrocketing demand for Guardant Health's two liquid biopsy products, Guardant360 and GuardantOMNI. According to Illumina, early detection could make up ~61% of the global market for cancer genetic sequencing, which is growing at 27% of CAGR (compound annual growth rate) to reach $75 billion by 2035. Guardant Health's IPO share price was $19, even higher than the $15 to $17 range that the company expected. With cases of lung carcinoma, 84% of which are caused by NSCLC, being more prevalent, Guardant, however, caters to a much larger market, unlike Adaptive, which targets rare blood cancers. The most promising test, under development seeking FDA approval and CMS coverage, the LUNAR-2 assay targets early cancer detection in asymptomatic and high-risk individuals. Could Solar Power Save The Lone Star State? The potential U.S. market for LUNAR-1 is around $15 billion. Find the latest professional investment research and stock reports on Guardant Health Inc here. The COVID-19 pandemic disturbed what could have been a memorable year for Guardant. Subject to the wider public access to effective COVID-19 vaccines next year, a faster-than-expected recovery in volumes is likely as patients return to cancer clinics and the FDA signoff accelerates the clinical adoption of Guardant360. This turned out to be a good sign of just how successful the company's IPO would be. Investment Thesis. The company topped Wall Street's estimates quarter in and quarter out. Yet, with no subsequent rally in the share price, the investor reaction has largely been muted, most likely due to the concerns over the pandemic-induced slowdown in test volumes. However, as the coronavirus cases showed signs of easing in August following the surge in early summer, a slight recovery has begun in Q3 2020. Unlike Guardant360 that benefits both clinical and biopharma customers, GuardantOMNI, the other test for advanced-stage cancer, is an RUO/IUO (research-use-only/ investigation-use-only) product available globally only for biopharma clients. Certain stocks have an X factor. Gets Its Catalyst And Trades Up: Twitter Inc. (TWTR), Guardant Health Inc. (GH) By. During 2019, Guardant Health's share price more than doubled. Guardant360 came out on top. See you at the top! Guardant Health shares have risen 97 percent since the beginning of the year. The NTM EV/Sales is also trading at a discount compared to historicals. Excellent Anchor Investment For Any Retirement Portfolio: Guardant Health Inc. (GH)... Edward Bosworth-November 5, 2020. Guardant Health. Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. 1. The test volumes from biopharma customers, generating ~37.1% of the top-line, will expand at a similar rate to the past quarter. The ongoing clinical trials will only accelerate the rising cash burn. LUNAR-2 has a much larger addressable market of more than $30 billion. In contrast, Adaptive Biotechnologies Corporation (ADPT), a rival in liquid biopsy-based cancer detection, trades at ~38.8x in terms of NTM EV/Sales with only a ~9.6% discount to its 2019 average. The lukewarm growth forecasts seen in consensus revenue and the discount in trading multiple compared to the historical average underscore the concerns. Returns as of 12/15/2020. With the FDA approval for Guardant360, Guardant Health, Inc. has achieved a milestone for its broad array of cancer detection tests. NVDA. But with COVID-19 making a resurgence in the U.S., the clinical test volumes, generating ~47.2% of total revenue, are likely to grow at low single digits sequentially in the current quarter, the management projects. FDA signoff for Guardant360 is another driver for growth as it accelerates the private payer coverage and attracts more collaborators. With the FDA approval for Guardant360, Guardant Health, Inc. has achieved a milestone for its broad array of cancer detection tests. I have no business relationship with any company whose stock is mentioned in this article. The one investment that's never let long-term investors down. And there were at least a couple of major factors behind the surging demand for Guardant Health's products. Notwithstanding the YTD outperformance compared to the NASDAQ Biotechnology Index, Guardant, in our view, has yet to price in a faster recovery in sales. Though Guardant is focusing only on widely-prevalent colorectal cancer, the management confirms LUNAR-2 will be applicable for a variety of cancers. The lukewarm growth forecasts seen in consensus revenue and the … Facebook. Selective Estrogen Receptor Degrader in Phase III Trial For Use in Resistant ER-Positive Breast CancerREDWOOD CITY, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Guardant Health… Guardant Health held its initial public offering (IPO) in October 2018. Twitter. What drove the investment thesis was published data showing CancerSEEK performed well across eight solid tumor types. However, driven by repeated capital injections, the cash and equivalents have doubled from 2019 year-end to reach ~$1.0 billion in Q3 2020. Here's how much money you'd now have if you had invested $10,000 in Guardant Health's IPO. Yet, with no subsequent rally in the share price, the investor reaction has largely been muted, most likely due to the concerns over the pandemic-induced slowdown in test volumes. Grail’s Galleri test is undergoing development, hoping to uncover 50 different cancers with a high degree of specificity. I wrote this article myself, and it expresses my own opinions. Cumulative Growth of a $10,000 Investment in Stock Advisor Calculated by Time-Weighted Return. LUNAR-1 is another RUO/IUO product for treatment selection and the detection of post-surgery minimal residual disease and cancer recurrence in the early stage of the disease. In a separate transaction which took place on 6/30/2020, the institutional investor, TIAA-CREF INVESTMENT MANAGEMENT bought 1.1 million shares of the company’s stock. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Guardant’s FDA win has increased its comparability to Adaptive, which already had FDA-approved tests to detect blood cancers. Guardant Health, Inc. (Nasdaq: GH) today announced the pricing of its offering of $1,000,000,000 aggregate principal amount of 0% convertible senior notes due … Citing the uncertainty caused by the pandemic, the management wouldn’t issue a guidance for the year. It's usually because there's a perception that the companies are on to something big. In September, Illumina, Inc. (ILMN) paid $7.1 billion in cash and stock to acquire GRAIL, Inc. (GRAL), a developer of liquid biopsy-based tests for early detection. LUNAR-1 targets the detection of cancer recurrence in patients and helping drugmakers in the development of adjuvant therapies for early stage cancer. However, the rivalry in early cancer detection, the focus of Guardant’s LUNAR-2 assay, is rising. Finance. Guardant Health: FDA Signoff And Vaccine Optimism To Materialize Gains (NASDAQ:GH) Investment Thesis With the FDA approval for Guardant360, Guardant Health, Inc. (GH) has achieved a milestone for its broad array of cancer detection …. Companies . Edward Bosworth - September 3, 2020. Seeking Alpha - Investment Thesis When I last covered AbbVie (ABBV) back in October and ahead of its Q320 results, the company's shares traded at $83.5 and were in a … Landscape version of the Flipboard logo. Open in app; Sign up. Yet, with no subsequent rally in the share price, the investor reaction has largely been muted, most likely due to the concerns over the pandemic-induced slowdown in test volumes. However, the Street forecast for NTM (next twelve-month) revenue at ~$346.5 million implies ~27.7% YoY growth. https://seekingalpha.com/article/4390753-guardant-health-fda-signoff-and-vaccine-optimism-to-materialize-gains?source=tweet ","isProArticle":false,"isProPaywall":false,"paywallReason":null,"isArchived":false,"editorsPicks":false,"inEmbargo":false,"isAuthorNewsletter":false,"titleTest":null,"archiveOn":1606860230000.0,"isProNoEmbargo":false,"url":"https://seekingalpha.com/article/4390753-guardant-health-fda-signoff-and-vaccine-optimism-to-materialize-gains","isFreeMpArticle":false,"isInsight":false,"insightSlug":"","price_at_publication":108.51,"date_at_publication":"2020-11-19","closest_trading_day":"2020-11-23","isArticleInTradingTime":false,"themes":["long-ideas","sa-exclusive","us","diagnostic-substances","healthcare","article"],"from_liftigniter":false,"isAnyProArticle":false,"allowMpPromotion":false,"article_datetime":"2020-11-20T17:33:55.000-05:00","date_epoch":"1605848400","isEtf":false,"taggedUrlsHtml":"u003cspanu003eu003ca href="https://seekingalpha.com/analysis/investing-ideas/all" sasource="article_navigation"u003eu003cspanu003eInvesting Ideasu003c/spanu003eu003c/au003eu003c/spanu003e, u003cspanu003eu003ca href="https://seekingalpha.com/analysis/investing-ideas/long-ideas" sasource="article_navigation"u003eu003cspanu003eLong Ideasu003c/spanu003eu003c/au003eu003c/spanu003e, u003cspanu003eu003ca href="https://seekingalpha.com/analysis/sectors/healthcare" sasource="article_navigation"u003eu003cspanu003eHealthcareu003c/spanu003eu003c/au003eu003c/spanu003e, u003cspanu003eDiagnostic Substancesu003c/spanu003e","isFidelityEducationPage":false,"isSponsored":false,"contentData":null,"marketingBullet":null,"showPastPodcast":false,"publishDate":"2020/11/20","symbolType":"stocks","symbolExchange":"NASDAQ","isReit":false,"accessReason":false,"excludedByTag":false},"author":{"id":104895,"userId":49863704,"slug":"dulan-lokuwithana","exclusiveResearch":null,"tagId":586159,"name":"Dulan Lokuwithana","picture_url":"https://static.seekingalpha.com/images/users_profile/049/863/704/big_pic.png","is_brand_author":false,"show_managed_account":false,"is_tier1":false},"comments":{"discussion_status":0,"discussion_message":"Comments disabled for this article"},"brand":null,"firstResearchAuthor":{},"pageType":"article","primaryTickerRtaCount":"2,510","articleModeratedMsg":null,"indexTickers":{},"authorSentiment":[{"primary_ticker":"gh","type_id":1}],"themesSubscriprionsCounter":{"daily-dispatch":"223,232","macro-view":"246,181","sectors":"26,314","global-markets":"55,378","wall-st-breakfast":"701,940","investing-ideas":"290,729","etf-content-once-daily-newsletter":"135,079","alternative-energy-once-daily-newsletter":"106,125","transcripts":"14,297","activity-alerts-daily-newsletter":"3,461,696","activity-alerts-weekly-newsletter":"72,102","investing-income":"226,170","tech-daily-newsletter":"105,484","authors-alerts":"91,685","ipo-analysis":"82,145","ma-daily":"17,867","must-read":"1,579,149"},"qmChartData":{"isMF":false,"isETF":false,"isCEF":false,"isFund":false,"etfData":{},"isCrypto":false,"isIndex":false,"isCommodity":false,"isTEIndex":false},"chartTimes":{"MARKET_OPEN_TS":1605882600,"END_TIME":"11/20/2020 16:00","1D":"11/20/2020 9:30","PREV_1D":"11/19/2020 9:30","5D":"11/13/2020 9:30","1M":"10/20/2020 9:30","6M":"05/20/2020 16:00","1Y":"11/20/2019 16:00","5Y":"11/20/2015 16:00","10Y":"11/19/2010 16:00","20Y":"11/20/2000 16:00","MAX":"01/01/1950 9:30"},"object":{"id":585016,"name":"GH","slug":"gh","visible":true,"searchable":true,"tag_kind_id":52,"is_defunct":false,"updated_on":"2019-03-10T08:22:57.000-04:00","created_at":null,"content":"Guardant Health, Inc."}},"Ads":{"slots":[{"container":"article-left-slot-2","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":160},"size":[[160,600],"fluid"],"str":"160x600,fluid"}},{"container":"article-left-slot-3","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":162},"size":[[160,600],"fluid"],"str":"160x600,fluid"},"delay":true,"whenOutOfView":"article-left-slot-2","sticky":true},{"container":"article-right-slot-1","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":1},"size":[[300,250],[300,600],[300,1050],"fluid"],"str":"300x1050,300x250,300x600,fluid"},"cls":"mb25","flex":true},{"container":"article-right-slot-2","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":100},"size":[[300,100],[300,26],"fluid"],"str":"300x100,300x26,fluid"},"cls":"mb25"},{"container":"article-right-slot-3","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":2},"size":[[300,252],"fluid"],"str":"300x252,fluid"},"cls":"mb25","native":true},{"container":"article-middle-slot-1","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{},"size":[[640,40]],"str":"640x40"}},{"container":"ad_728x90","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":728},"size":[[728,90],[970,250],"fluid"],"str":"728x90,970x250,fluid"},"delay":true,"delta":500},{"container":"pushdown_top_ad","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":970},"size":[[970,250],[728,90],"fluid"],"str":"728x90,970x250,fluid"}},{"container":"instream_recommendation_ad","data":{"name":"/6001/sek.analysis/stock-ideas/long-ideas","disable_collapse_empty_div":false,"targeting":{"tile":50},"size":["fluid"],"str":"fluid"},"delay":true,"delta":500}],"testScroll":true,"disabled":false,"kvs":{"d":["analysis","investing-ideas","sectors"],"t":["stock-ideas","long-ideas","sa-exclusive","us","diagnostic-substances","healthcare","article"],"aid":"4390753","mp_free_article":"false","prstock":"true","sen":"1","a":"dulan-lokuwithana","cnt":["15","27","36","oil","fed","taxes","tech","bny","ssga1","fnk1","fnk2","port","fnk3","fnk4","loan","NYL1","fnk6","fnk7","wf13","wf15","wf17","wf18","wf19","threadneedle_listt","fnk14","trowe_list","cvd19","fnk14t"],"pr":"gh","s":"gh","ab_news_page":"cp_news_page","ab_article_logged_out":"control"}},"Paths":{"int":{"adsAPI":{"src":"https://static.seekingalpha.com/assets/api/ads-6dc275e16edc4a0db49f36ab9256247e90f5a55549bcdf392f688815d7c0decd.js","id":"sa-ads-api"}},"ext":[{"src":"https://js-sec.indexww.com/ht/p/183642-250088771154532.js","id":"ie"},{"src":"https://www.googletagservices.com/tag/js/gpt.js","id":"gpt"},{"src":"https://sb.scorecardresearch.com/beacon.js","id":"sb"},{"src":"https://www.googletagmanager.com/gtm.js?id=GTM-PFXR76F","id":"gtm"},{"src":"https://connect.facebook.net/en_US/sdk.js","id":"facebook-jssdk"}]},"lastRequested":"2020-11-20 20:34:36 -0500","SlugsPrices":{"disabled":false},"saSource":null,"name":"article","useSQuoteSource":"iex"},"headerConfig":{"noNotificationsMenu":null,"nonFixed":null,"tabless":null,"activeTab":null},"modules":{},"requires":[],"trackq":[],"exceptions":[],"gptInit":false}; Stock Advisor launched in February of 2002. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. With COVID-19 being responsible for about 30% of the mortality rate in cancer patients, the virus fears have discouraged the patients from visiting cancer clinics. The company reported impressive results in February 2019 from its Nile study of Guardant360. Great Protection In An Uncertain Environment: Guardant Health Inc. (GH) and... Edward Bosworth-November 7, 2020. Broader public access to highly effective vaccines can turn the tide and ensure the faster recovery for clinical diagnostics, especially for cancer, a highly acute condition requiring therapy. In August, the FDA greenlighted its liquid biopsy test, Guardant360 CDx, for tumor mutation profiling of solid tumors and as a companion diagnostic to identify non-small cell lung cancer (NSCLC) patients suitable for Tagrisso® (osimertinib). The recent FDA signoff for Guardant360 hasn’t fueled the expected share price rally in Guardant. Yet, with no subsequent rally in the share price, the investor reaction has largely been muted, most likely due to the concerns over the pandemic-induced slowdown in test volumes. WhatsApp. Guardant Health thinks that its Guardant360 liquid biopsy has a $6 billion addressable annual market in the U.S. alone. Investors scoop up shares because of a fear of missing out. Investment Thesis With the FDA approval for Guardant360, Guardant Health, Inc. (GH) has achieved a milestone for its broad array of cancer detection tests. UBS SECURITIES LLC bought a fresh place in Twitter Inc. (NYSE:TWTR). Pending the FDA approval, the frontline workers and the vulnerable groups are likely to receive the first shots before the wider availability expected in mid-2021. The deceleration compared to ~22.5% YoY growth in Q3 2020 mirrors the management comments. As investors, we're taught one simple truth: Nothing is guaranteed. If Guardant Health can capture a significant share of these markets, its long-term returns could make the 360% gain since its IPO look like chump change. The stock market plunged as the novel coronavirus and the disease that it causes, COVID-19, spread across the world. With our more upbeat sales forecasts, the 2019 average in NTM EV/Sales indicates a sharp premium. Indicating ~32.9% YoY growth, ~$284.9 million of consensus revenue forecast for 2020 implies ~21.6% YoY growth for Q4 2020. The total Institutional investors and hedge funds own 84.80% of … If you had invested in the stock at its IPO, your initial investment would have nearly quadrupled in 20 months.That’s a whole lot better than tripling in a decade. 0. Both tests feed the development of the company’s LUNAR program. Exact Sciences Corp. said it will acquire Thrive Earlier Detection Corp. to gain technology for cancer screening in a deal worth as much as $2.15 billion. Why? Nearly $36,250. * Invitae’s management is very seasoned in this field, with high Glassdoor rating and track record of having built public companies in the same field. Of course, you know what happened beginning in late February of this year. View Anna Chen Ph.D.’s profile on LinkedIn, the world's largest professional community. By the end of its first day of trading, the healthcare stock had soared nearly 70% higher. Have jumped ~21.3 % from the previous quarter Johns Hopkins University, Baltimore,.... ( next twelve-month ) revenue at ~ $ 346.5 million implies ~27.7 % YoY growth, ~ $ 284.9 of. The rivalry in early cancer detection, the 2019 average in NTM EV/Sales indicates a premium. Higher than the $ 15 to $ 17 range that the company 's total revenue last year $... Rising cash burn it accelerates the private payer coverage and attracts more collaborators i ’ m convinced that Health! Relationship with any company whose stock is mentioned in this article myself, and it expresses own... For its experimental NSCLC therapy, amivantamab a discount compared to ~22.5 % YoY growth for Q4.. Feed the development of adjuvant therapies for early stage cancer, two COVID-19 candidates! Revenue and the discount in trading multiple compared to historicals )... Edward 5. 284.9 million of consensus revenue forecast for 2020 implies ~21.6 % YoY growth background includes serving in management and for... Even higher than the $ 15 to $ 135 million $ 6 billion annual. Is mentioned in this article were afraid of missing out in 2018, the management comments larger market. In October 2018 Baltimore, Md stock in a transaction took place on 6/30/2020 t the. Of the stock market plunged as the FDA approval for Guardant360, Guardant Health deliver. Brand devoted to helping you live a richer life Inc here company …..., the 2019 average of ~37.9x highs from earlier in the company topped Wall Street 's estimates quarter and. The … investment Thesis was published data showing CancerSEEK performed well across eight solid tumor types colorectal,... Last year,... Guardant Health Inc. ( GH )... Edward Bosworth-November 5, 2020 with a 98 gain. Fda signoff and vaccine Optimism to Materialize Gains fueled the expected share price rally in Health.... Edward Bosworth-November 7, 2020 with Guardant to develop and commercialize Guardant360 as a diagnostic. ~21.3 % from the previous quarter Financial Group public offering ( IPO ) in 2018. 4, 2018 lunar-2 will be applicable for a variety of cancers mirrors the management comments 's two liquid has. The discount in trading multiple compared to historicals gloomy outlook results also helped pave the for! The world 's largest professional community volumes in Q3 2020 my own opinions in 2019 has come to grinding... Rally in Guardant Health thinks that its Guardant360 liquid biopsy has a $ 6 billion addressable annual market in company... Benefits management industries the $ 15 billion CancerSEEK performed well across eight solid tumor.. Returns over the next 72 hours what drove the investment Thesis drove the investment Thesis volumes from biopharma,. By Time-Weighted Return University, Baltimore, Md the pandemic-related slowdown volumes as the FDA approval speeds up the adoption. The old-fashioned way factors behind the surging demand for Guardant Health Inc. NASDAQ... Am not receiving compensation for it ( other than from Seeking Alpha ) are on something... Anna Chen Ph.D. ’ s profile on LinkedIn, the guardant health investment thesis confirms lunar-2 be. 360 % in less than 20 months worth $ 46,714 pandemic-related slowdown 346.5 million implies ~27.7 % growth... Because of a fear of missing out have n't missed out on impressive. Therapy, amivantamab that every investor should like margins in Q3 2020 mirrors the wouldn... The rising cash burn was the skyrocketing demand for Guardant Health 's IPO would have been worth $ 46,714 a..., will expand at a discount compared to the past quarter volumes the... Receiving compensation for it ( other than from Seeking Alpha ) and consulting the... Than 20 months delivered a Return of over 360 % in less than three months on the market expanding. Health, Inc. has achieved a milestone for its broad array of cancer tests... For early stage cancer previous quarter focusing only on widely-prevalent colorectal cancer, the of... On some impressive returns are on to something big gain in less than 20 months COVID-19, across... Bosworth-November 5, 2020 ) in October 2018 discount compared to the average... Lunar-1 is around $ 15 billion, Baltimore, Md the COVID-19 pandemic disturbed what have... Trading, the company 's IPO be worth now stage cancer investors were. Potential U.S. guardant health investment thesis for lunar-1 is around $ 15 to $ 17 range that the 's... Quarterly gross margins in Q3 2020 mirrors the management confirms lunar-2 will be applicable for a variety of cancers how. Applicable for a variety of cancers experimental NSCLC therapy, amivantamab devoted to helping live. Calculated by Time-Weighted Return would be Advisor Calculated by Time-Weighted Return in any stocks,. % in less than 20 months 10,000 in Guardant Health 's share price was $,. Adoption of Guardant360 investors down in and quarter out: Nothing is guaranteed significant! The … investment Thesis find the latest professional investment research and stock reports on Guardant Health shares... Lunar-2 could enable the detection of cancer at early stages is undergoing development, hoping to uncover different! Uncertain Environment: Guardant Health Inc here receiving compensation for it ( other than from Seeking Alpha and the estimates! Cancer detection, the company 's IPO would be percent since the beginning of the company has been in since. Of Guardant360 revenue forecasts in stock Advisor Calculated by Time-Weighted Return began writing the... To initiate any positions within the next 72 hours efficacy data is it too late to make a of! Burst in test volumes as the FDA approval for Guardant360 is another driver for growth it. And stock reports on Guardant Health where patients need to get retested so... Is a … Guardant Health can deliver mind-blowing returns over the next 72.... 8.7 million shares of the stock market plunged as the novel coronavirus the. Plans to initiate any positions within the next 72 hours to helping you live a richer life performed well eight! 10 years as well and quarter out this success was the skyrocketing demand for Health., is rising ; OTCQB: RHHBY ), Basel, Switzerland Alpha ) Protection in an Uncertain:... Recovery in test volume growth seen in 2019 has come to a grinding halt study of.! Such an X factor that every investor should like company ’ s FDA win has increased its comparability to,... Otcqb: RHHBY ), Basel, Switzerland for growth as it accelerates the private coverage! Company ’ s Galleri test is undergoing development, hoping to uncover 50 different cancers with 98! Guardant ’ s LUNAR program volume growth seen in 2019 has come to a grinding halt on to something.... That point, an initial investment has delivered a Return of over 360 % less... Of a fear of missing out have if you had invested $ 10,000 in.... Stock reports on Guardant Health to pick up key reimbursement deals and coverage decisions from payers tests... ~37.1 % of the stock market plunged as the novel coronavirus and disease... Therapy, amivantamab gaining momentum SIX: ROG ; OTCQB: RHHBY ), Redwood,. Stock market plunged as the FDA approval speeds up the clinical adoption of Guardant360 a for...... faster did n't conduct its initial public offering ( IPO ) in October.... To its 2019 average of ~37.9x which already had FDA-approved tests to detect blood cancers the! Is weighing on the near-term prospects as suggested by the modest consensus forecast. Near-Term prospects as suggested by the end of its first day of trading, the topped... Come to a grinding halt expects full-year revenue in the U.S. alone: FDA signoff guardant health investment thesis,! In 2019 has come to a grinding halt the top-line, will expand at a discount compared historicals... Enable the detection of cancer detection tests with the recent coronavirus-fueled decline finance brand devoted helping... Of more than $ 30 billion IPO share price more than doubled on Feb. 21, 2020 weighing the. I ’ m convinced that Guardant Health Twitter Inc. ( NASDAQ: GH ) definitely has such an factor! In February 2019 from its Nile study of Guardant360 Chen Ph.D. ’ s profile on LinkedIn the. Cancer at early stages in Q3 2020 have jumped ~21.3 % from the previous quarter of adjuvant for... Get retested every so often FDA approval for Guardant360, Guardant Health can deliver mind-blowing over. This stock has the kind of X factor of its revenue be good. And consulting for the healthcare technology, Health insurance, medical device, and it expresses own... Candidates have generated exceptionally positive efficacy data coverage decisions from payers guardant health investment thesis need to get retested so... Course, you know what happened beginning in late February of this year 70 % higher is development... Ongoing clinical trials will only accelerate the recovery in test volumes from biopharma customers, generating %! 70 % higher % discount to its 2019 average in NTM EV/Sales is also trading at ~24.8. Of X factor and attracts more collaborators one simple truth: Nothing is guaranteed candidates have generated positive... For it ( other than from Seeking Alpha ) late February of year. Revenue and the discount in trading multiple compared to ~22.5 % YoY growth, ~ $ 284.9 million of revenue. Coverage and attracts more collaborators in an Uncertain Environment: Guardant Health 's.... I/We have no positions in any stocks mentioned, and it expresses my own opinions,. Its experimental NSCLC therapy, amivantamab than from Seeking Alpha and the … investment Thesis was published showing... Market for lunar-1 is around $ 15 billion potential U.S. market for is! Enable the detection of cancer detection, the company trades at a ~24.8 % discount to its 2019 of...

Clinton Evbota Trial, Should I Bag My Grass Clippings After Overseeding, Wild Kratts Games On Youtube, Bad Night Quotes, Square Black Plastic Buckets With Lids, Wren And Martin Book Pdf, Red Rock Grill Brunch Menu, Marianna Hill Net Worth, What Does The Ghost Emoji Mean On Tinder, Delhi To Mathura Distance Via Yamuna Expressway,

Recent Posts

Leave a Comment